宁科生物（600165）投资者索赔再提交立案，已有胜诉及获赔到位

Core Viewpoint - The article discusses the legal actions taken against Ningke Biological (600165) for false statements in its financial reporting, highlighting the ongoing investor compensation efforts and the company's regulatory violations. Group 1: Legal Actions and Compensation - The Shanghai Jiucheng Law Firm, represented by lawyer Xu Feng, has submitted a new case for investor compensation related to Ningke Biological's false statements, with some investors already receiving compensation [1][5] - The law firm continues to accept claims from other investors affected by the company's actions [1][5] Group 2: Regulatory Violations - Ningke Biological's 2022 annual report contained false records, inflating revenue by 76.5941 million yuan and profit by 77.222 million yuan, which accounted for 11.25% and 46.59% of the total revenue and profit, respectively [5] - The company failed to timely disclose significant events, including major debts and the freezing of key bank accounts [2][6] - Additionally, the company did not disclose that a subsidiary's main business had come to a halt [3][5]